499 related articles for article (PubMed ID: 26815727)
1. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
[TBL] [Abstract][Full Text] [Related]
2. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Marcelli C; Bardin T; Pane I; Baron G; Mariette X
Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
[TBL] [Abstract][Full Text] [Related]
3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
4. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
5. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
[TBL] [Abstract][Full Text] [Related]
6. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
[TBL] [Abstract][Full Text] [Related]
7. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor.
Ajeganova S; van Steenbergen HW; Verheul MK; Forslind K; Hafström I; Toes RE; Huizinga TW; Svensson B; Trouw LA; van der Helm-van Mil AH
Ann Rheum Dis; 2017 Jan; 76(1):112-118. PubMed ID: 27117699
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.
Kida D; Takahashi N; Kaneko A; Hirano Y; Fujibayashi T; Kanayama Y; Hanabayashi M; Yabe Y; Takagi H; Oguchi T; Kato T; Funahashi K; Matsumoto T; Ando M; Kuwatsuka Y; Tanaka E; Yasuoka H; Kaneko Y; Hirata S; Murakami K; Sobue Y; Nishiume T; Suzuki M; Yokota Y; Terabe K; Asai S; Ishiguro N; Kojima T
Sci Rep; 2020 Nov; 10(1):19717. PubMed ID: 33184461
[TBL] [Abstract][Full Text] [Related]
9. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
10. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
11. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
12. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
Iannone F; Courvoisier DS; Gottenberg JE; Hernandez MV; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Choquette D; Finckh A
Clin Rheumatol; 2017 Apr; 36(4):773-779. PubMed ID: 27966068
[TBL] [Abstract][Full Text] [Related]
13. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
[TBL] [Abstract][Full Text] [Related]
14. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
Aletaha D; Alasti F; Smolen JS
Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
[TBL] [Abstract][Full Text] [Related]
16. Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.
Alemao E; Postema R; Elbez Y; Mamane C; Finckh A
Clin Exp Rheumatol; 2020; 38(3):455-466. PubMed ID: 31770089
[TBL] [Abstract][Full Text] [Related]
17. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
[TBL] [Abstract][Full Text] [Related]
18. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
[TBL] [Abstract][Full Text] [Related]
19. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G
Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448
[TBL] [Abstract][Full Text] [Related]
20. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.
Barra L; Bykerk V; Pope JE; Haraoui BP; Hitchon CA; Thorne JC; Keystone EC; Boire G;
J Rheumatol; 2013 Aug; 40(8):1259-67. PubMed ID: 23378461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
